ALPMY
Astellas Pharma, Inc.
Other OTC
People also watch:TKPYYDSNKYESALYSVNDYTKOMY
16.180.45 (2.84%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close15.73
Open16.18
Bid0.00 x
Ask0.00 x
52wk Range12.50 - 16.67
Day's Range16.12 - 16.20
Volume55,906
Avg Vol (3m)72,252
As of 10:24 AM EDT. Other OTC Delayed Price. Market open.
  • Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting
    Insider Monkey5 days ago

    Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics Inc. (PSTI) Are Benefiting

    Japan is the stem cell capital of the world. From the Nobel winning efforts of Shinya Yamanaka in the field of mature to pluripotent stem cell reprogramming, to the STAP scandal and its suicide tarnished fallout, if there’s something to talk about in the sector, chances are it happened first in Japan. Japan’s development of […]

  • Reuters2 months ago

    Genentech, OSI to pay $67 mln over drug claims - U.S. Justice Dept

    Pharmaceutical companies Genentech and OSI Pharmaceuticals LLC will pay $67 million to resolve allegations they made misleading statements about the effectiveness of lung cancer drug Tarceva, the U.S. Justice Department said on Monday. The claims alleged that between 2006 and 2011, the companies misrepresented the effectiveness of Tarceva to physicians and other healthcare providers to treat certain patients with non-small cell lung cancer, the department said in a statement.